Panel Discussion

Q. Which tests you usually consider for detecting uncommon mutations in patients with NSCLC? NGS or RTPCR?

Q. What are the commonest challenges that you see to achieve broader NGS based or multi gene testing? What possible interventions apart from the cost we should take to improve the adoption of NGS?

Q. What are the triggering factors/patients’ characteristics which prompts you to consider for testing of uncommon mutations like Exon20ins mutations?

Q. In your experience what is the prognosis of patients with EGFR Exon 20 insertions compared to those with common EGFR mutations or other NSCLC?

Q. What is your experience with treating EGFR Exon 20 insertion patients?

Q. What drives you to choose your first line/second line of therapy in EGFR Exon 20 insertion patients?

Q. What is your initial impression on efficacy and safety of Amivantamab in patients with Exon20ins mutations?

Q. What will be the ideal patient profile who will benefit most from Amivantamab therapy?

Q. What are the potential challenges for the use of Amivantamab in advanced NSCLC patients with EGFR Exon20ins mutation in India apart from cost of therapy?

Q. What is your opinion regarding infusion related reactions associated with Amivantamab? What precautions should be taken to reduce the incidence of IRRs?